Detection/NN
of/IN
Mycoplasma/NN
Infection/NN
in/IN
Cultured/JJ
Cells/NNS
on/IN
the/DT
Basis/NN
of/IN
Molecular/JJ
Profiling/JJ
of/IN
Host/NN
Responses/NNS
./.
====================
Adaptive/JJ
responses/NNS
to/TO
diverse/JJ
microbial/JJ
pathogens/NNS
might/MD
be/VB
limited/JJ
in/IN
relatively/RB
few/JJ
types/NNS
./.
====================
Host/NN
cell/NN
responses/NNS
to/TO
====================
pathogens/NNS
are/VBP
believed/VBN
to/TO
be/VB
patterned/VBN
or/CC
stereotyped/JJ
along/IN
with/IN
species/NNS
or/CC
class/NN
./.
====================
We/PRP
tried/VBD
to/TO
compose/VB
the/DT
host/NN
response/NN
to/TO
Mycoplasma/NN
in/IN
terms/NNS
of/IN
cellular/JJ
gene/NN
expression/NN
./.
====================
Although/IN
gene/NN
expression/NN
profile/NN
of/IN
two/CD
host/NN
HeLa/NN
and/CC
293/CD
cells/NNS
were/VBD
quite/RB
different/JJ
each/DT
other/JJ
,/,
30/CD
genes/NNS
were/VBD
differentially/RB
expressed/VBN
by/IN
mycoplasma/NN
infection/NN
in/IN
both/DT
of/IN
HeLa/NN
and/CC
293/CD
cells/NNS
./.
====================
Six/CD
of/IN
them/PRP
(/(
PR48/NN
,/,
MADH4/NN
,/,
MKPX/NN
,/,
CRK/NN
,/,
RBM7/NN
,/,
NEK3/NN
)/)
were/VBD
related/JJ
to/TO
cell/NN
cycle/NN
or/CC
proliferation/NN
./.
====================
Another/DT
category/NN
of/IN
genes/NNS
like/IN
IL1HY1/NN
,/,
KLRF1/NN
,/,
TNFSF14/NN
,/,
GBP1/NN
were/VBD
host/NN
defense/NN
to/TO
elicit/VB
immune/JJ
responses/NNS
./.
====================
With/IN
this/DT
set/NN
of/IN
genes/NNS
,/,
we/PRP
establish/VBP
the/DT
prediction/NN
model/NN
for/IN
mycoplasma/NN
contamination/NN
./.
====================
The/DT
Mycoplasma/NN
,/,
with/IN
over/IN
100/CD
different/JJ
species/NNS
,/,
are/VBP
the/DT
smallest/JJS
self-replicating/VBG
organisms/NNS
known/VBN
at/IN
present/JJ
and/CC
constitute/VBP
a/DT
distinct/JJ
class/NN
within/IN
the/DT
prokaryotes/NNS
characterized/VBN
by/IN
their/PRP$
lack/NN
of/IN
a/DT
rigid/JJ
cell/NN
wall/NN
./.
====================
They/PRP
can/MD
be/VB
classified/VBN
into/IN
fermentative/JJ
strains/NNS
,/,
which/WDT
gain/VBP
energy/NN
by/IN
fermentation/NN
of/IN
carbohydrates/NNS
and/CC
non-fermentative/JJ
strains/NNS
that/DT
are/VBP
unable/JJ
to/TO
metabolize/VB
carbohydrates/NNS
via/IN
glycolysis/NN
./.
====================
The/DT
mycoplasmas/NNS
are/VBP
extra/JJ
cellular/JJ
parasites/NNS
usually/RB
attached/VBN
to/TO
the/DT
external/JJ
surface/NN
of/IN
cells/NNS
,/,
but/CC
can/MD
also/RB
penetrate/VBP
these/DT
(/(
Razin/NN
etal./FW
,/,
1998/CD
)/)
./.
====================
In/IN
humans/NNS
,/,
M./NNP
pneumoniae/FW
is/VBZ
a/DT
frequent/JJ
cause/VBP
of/IN
respiratory/JJ
infections/NNS
,/,
and/CC
is/VBZ
at/IN
the/DT
origin/NN
of/IN
approximately/RB
20/CD
%/NN
of/IN
all/DT
community-/NN
acquired/VBN
pneumonias/NNS
(/(
Hammerschlag/NN
,/,
2001/CD
)/)
./.
====================
Being/VBG
====================
'minimal/JJ
cells/NNS
'/``
,/,
Mycoplasma/NN
have/VBP
also/RB
been/VBN
used/VBN
to/TO
investigate/VB
the/DT
machinery/NN
of/IN
self-replicating/VBG
organisms/NNS
(/(
Razin/NN
,/,
1992/CD
)/)
./.
====================
Beside/IN
health/NN
problems/NNS
,/,
mycoplasma/NN
contamination/NN
constitutes/VBZ
one/CD
frequent/JJ
problem/NN
when/WRB
studying/VBG
cultured/VBN
cells/NNS
(/(
estimated/VBN
frequency/NN
varying/VBG
from/IN
5/CD
to/TO
35/CD
%/NN
)/)
./.
====================
The/DT
strains/NNS
M./NNP
hyorhinis/NN
,/,
M./NNP
orale/JJ
,/,
M./NNP
arginini/NNS
,/,
M./NNP
fermetans/JJ
,/,
M./NNP
hominis/NN
and/CC
Acholeplasma/NN
laidlawii/LS
represent/JJ
90-95/CD
%/NN
of/IN
the/DT
contaminating/VBG
isolates/NNS
(/(
Hay/NN
et/FW
al./FW
,/,
1989/CD
)/)
./.
====================
Contamination/NN
is/VBZ
initially/RB
often/RB
difficult/JJ
to/TO
detect/VB
because/IN
the/DT
contaminated/JJ
culture/NN
grows/VBZ
well/RB
and/CC
appears/VBZ
normal/JJ
by/IN
ordinary/JJ
light/NN
microscopy/NN
./.
====================
In/IN
addition/NN
,/,
Mycoplasma/NN
is/VBZ
highly/RB
contagious/JJ
and/CC
can/MD
rapidly/RB
spread/VBN
through/IN
the/DT
cell/NN
stocks/NNS
./.
====================
The/DT
possible/JJ
consequences/NNS
of/IN
mycoplasma/NN
infection/NN
for/IN
the/DT
host-cells/NNS
are/VBP
multiple/JJ
and/CC
variable/JJ
,/,
ranging/VBG
from/IN
no/DT
apparent/JJ
effect/NN
to/TO
extensive/JJ
changes/NNS
with/IN
inhibition/NN
of/IN
cell/NN
proliferation/NN
,/,
induction/NN
of/IN
apoptosis/NN
,/,
induction/NN
of/IN
cytokines/NNS
and/CC
oxidative/JJ
radicals/NNS
,/,
and/CC
malignant/JJ
transformation/NN
(/(
Avron/NN
and/CC
Gallily/RB
,/,
1995/CD
;/:
Sokolova/NNP
etal./FW
,/,
1998/CD
;/:
Tsai/NNP
etal./FW
,/,
1995/CD
)/)
./.
====================
There/EX
is/VBZ
also/RB
a/DT
possibility/NN
that/IN
mycoplasmal/JJ
biological/JJ
activities/NNS
may/MD
erroneously/RB
be/VB
interpreted/VBN
as/IN
being/VBG
of/IN
host/NN
origin/NN
(/(
Choi/NNP
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Understanding/VBG
the/DT
molecular/JJ
basis/NN
of/IN
a/DT
host/NN
’/NN
s/NNS
response/NN
to/TO
microbial/JJ
infection/NN
is/VBZ
essential/JJ
for/IN
preventing/VBG
====================
disease/NN
and/CC
tissue/NN
damage/NN
as/IN
a/DT
result/NN
of/IN
the/DT
inflammatory/JJ
response/NN
./.
====================
A/DT
better/RBR
understanding/NN
of/IN
this/DT
process/NN
should/MD
allow/VB
for/IN
the/DT
design/NN
of/IN
drugs/NNS
that/WDT
can/MD
more/RBR
specifically/RB
and/CC
====================
effectively/RB
target/NN
infected/JJ
cells/NNS
with/IN
reduced/VBN
side-effects/NNS
./.
====================
The/DT
host-pathogen/NN
interaction/NN
can/MD
result/VB
in/IN
many/JJ
changes/NNS
to/TO
the/DT
host/NN
cell/NN
including/VBG
modulation/NN
of/IN
RNA/NN
expression/NN
,/,
target/NN
receptor/NN
induction/NN
,/,
actin/NN
cytoskeletal/JJ
rearrangements/NNS
,/,
signal/NN
transduction/NN
pathway/NN
activation/NN
,/,
and/CC
vacuolar/JJ
trafficking/VBG
(/(
Finlay/RB
and/CC
Cossart/NN
,/,
1997/CD
;/:
Cummings/NNS
and/CC
Reiman/JJ
,/,
2000/CD
)/)
./.
====================
DNA/NN
microarray/NN
enabled/VBD
us/PRP
to/TO
describe/VB
a/DT
unique/JJ
biological/JJ
phenomenon/NN
in/IN
terms/NNS
of/IN
genome-wide/NN
gene/NN
expression/NN
analysis/NN
./.
====================
It/PRP
can/MD
provide/VB
a/DT
bird-eye/NN
view/NN
on/IN
a/DT
certain/JJ
phenomenon/NN
as/IN
well/RB
as/IN
complete/JJ
list/NN
on/IN
the/DT
significant/JJ
genes/NNS
./.
====================
Gene/NN
expression/NN
profiling/VBG
using/VBG
DNA/NN
microarray/NN
has/VBZ
been/VBN
offering/VBG
potentials/NNS
for/IN
defining/VBG
the/DT
patterns/NNS
especially/RB
on/IN
gene/NN
expression/NN
during/IN
normal/JJ
biological/JJ
or/CC
disease/NN
processes/NNS
./.
====================
Moreover/RB
,/,
many/JJ
of/IN
differentially/RB
expressed/VBN
genes/NNS
that/WDT
may/MD
play/VB
an/DT
integral/JJ
role/NN
in/IN
these/DT
processes/NNS
were/VBD
identified/VBN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
have/VBP
utilized/VBN
spotted/VBN
oligonucleotide/NN
microarray/NN
to/TO
examine/VB
the/DT
expression/NN
of/IN
10,416/CD
known/VBN
====================
regulatory/JJ
genes/NNS
upon/IN
mycoplasma/NN
infection/NN
./.
====================
We/PRP
compare/VBP
the/DT
distribution/NN
of/IN
patterns/NNS
of/IN
gene/NN
expressions/NNS
in/IN
two/CD
different/JJ
cell/NN
lines/NNS
,/,
HeLa/NN
and/CC
293/CD
cells/NNS
./.
====================
After/IN
that/DT
we/PRP
select/VBP
30/CD
genes/NNS
that/WDT
expressed/VBD
differentially/RB
in/IN
both/CC
of/IN
HeLa/NN
and/CC
293/CD
cells/NNS
,/,
as/IN
biomarkers/NNS
for/IN
Mycoplasma/NN
infection/NN
./.
====================
Actual/JJ
prediction/NN
model/NN
for/IN
the/DT
infection/NN
is/VBZ
also/RB
discussed/VBN
./.
====================
We/PRP
used/VBD
HeLa/NN
and/CC
293/CD
cells/NNS
were/VBD
maintained/VBN
in/IN
Dulbeccos/NN
modified/VBN
Eagle/JJ
medium/NN
(/(
DMEM/NN
,/,
JBI/NNP
,/,
Seoul/JJ
,/,
Korea/NN
)/)
supplemented/VBD
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
(/(
JBI/NN
)/)
,/,
====================
1/CD
%/NN
Penicillin-Streptomycin/NN
(/(
Invitrogen/NN
)/)
./.
====================
Cells/NNS
were/VBD
plated/VBN
in/IN
concentration/NN
of/IN
2-5x10/CD
6/CD
per/FW
T75/NN
flask/NN
18/CD
h/NN
before/IN
mycoplasma/NN
infection/NN
./.
====================
M./NNP
hyoriniswere/VBP
harvested/VBD
at/IN
log/NN
phase/NN
to/TO
treat/VB
onto/IN
cells/NNS
at/IN
10/CD
8/CD
per/FW
T75/NN
flask/NN
./.
====================
After/IN
48/CD
h/NN
,/,
cells/NNS
were/VBD
washed/VBN
with/IN
phosphate/NN
buffered/JJ
saline/NN
and/CC
harvested/VBD
for/IN
RNA/NN
preparation/NN
./.
====================
Total/JJ
cellular/JJ
RNA/NN
was/VBD
prepared/VBN
using/VBG
RNAeasy/NN
total/JJ
RNA/NN
purification/NN
kit/NN
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NNP
)/)
followed/VBN
by/IN
treatment/NN
with/IN
RNase-free/JJ
RQ/NN
DNase/NN
(/(
Promega/NN
Corp./NNP
,/,
Madison/NN
,/,
Wl/NNP
)/)
./.
====================
For/IN
cDNA/NN
synthesis/NN
,/,
random/JJ
hexamer/NN
primers/NNS
(/(
Gibco/BRL/NN
)/)
were/VBD
used/VBN
to/TO
prime/JJ
reverse/JJ
transcriptase/NN
(/(
RT/NN
)/)
reactions/NNS
./.
====================
Using/VBG
this/DT
method/NN
it/PRP
was/VBD
possible/JJ
to/TO
use/VB
the/DT
same/JJ
RT/NN
reaction/NN
(/(
cDNA/NN
)/)
for/IN
PCR/NN
amplification/NN
with/IN
different/JJ
sets/NNS
of/IN
gene-specific/JJ
primers/NNS
./.
====================
The/DT
cDNA/NN
synthesis/NN
was/VBD
carried/VBN
out/RP
using/VBG
Moloney/NNP
murine/JJ
leukemia/NN
virus/NN
(/(
M-MLV/NN
)/)
Superscript/NN
II/CD
reverse/JJ
transcriptase/NN
(/(
Gibco/BRL/NN
)/)
following/VBG
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
To/TO
analyze/VB
relative/JJ
expression/NN
of/IN
different/JJ
mRNAs/NNS
,/,
the/DT
amount/NN
of/IN
cDNA/NN
was/VBD
normalized/VBN
based/VBN
on/IN
the/DT
signal/NN
from/IN
ubiquitously/RB
expressed/VBN
actin/NN
mRNA/NN
./.
====================
Total/JJ
RNAs/NNS
from/IN
control/JJ
or/CC
Mycoplasma-infected/JJ
HeLa/NN
or/CC
293/CD
cells/NNS
used/VBN
as/IN
to/TO
extract/NN
total/JJ
RNA/NN
for/IN
quantipli-/JJ
cated/VBD
experiment/NN
including/VBG
one/CD
dye-swapping/VBG
set/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
prepared/VBN
by/IN
using/VBG
TriZol/JJ
reagent/JJ
(/(
Gibco-BRL/NN
)/)
./.
====================
The/DT
array/NN
used/VBN
in/IN
this/DT
experiment/NN
was/VBD
MacArray/NN
(/(
Oligo-Human/JJ
10K/NN
,/,
Macrogen/NN
Inc./NNP
,/,
Seoul/JJ
,/,
Korea/NN
)/)
according/VBG
to/TO
the/DT
manual/JJ
provided/VBD
by/IN
manufacturer/NN
./.
====================
Briefly/RB
,/,
100/CD
/zg/NN
of/IN
total/JJ
RNA/NN
was/VBD
labelled/VBN
by/IN
incubating/VBG
it/PRP
with/IN
Cyanine-3-dUTP/NN
(/(
6.0/CD
mM/NN
)/)
(/(
Perkin/NN
Elmer/NN
Life/NN
Sciences/NNS
)/)
or/CC
Cyanine-5-dUTP/NN
(/(
4.0/CD
mM/NN
)/)
(/(
Perkin/NN
Elmer/NN
Life/NN
Sciences/NNS
)/)
,/,
dNTP/NN
mixture/NN
,/,
0.1M/CD
DTT/NN
,/,
RnaseOUT/NN
,/,
inorganic/JJ
pyrophosphatase/NN
,/,
reverse/JJ
transcriptase/NN
at/IN
40/CD
°C/NN
for/IN
3/CD
hours/NNS
./.
====================
Before/IN
hybridization/NN
,/,
8/CD
m/NN
of/IN
Cyanine-3-CTP/NN
====================
labelled/VBN
cRNA/NN
and/CC
8/CD
</JJR
zg/JJ
of/IN
Cyanine-5-CTP/NN
labelled/VBN
cRNA/NN
were/VBD
mixed/VBN
together/RB
with/IN
2.5/CD
id/JJ
of/IN
Mouse/NN
Cot-1/NN
DNA/NN
(/(
Invitrogen/NN
)/)
,/,
2.5/CD
id/JJ
of/IN
Deposition/NN
control/NN
target/NN
(/(
Operon/NN
Technologies/NNS
)/)
,/,
and/CC
12.5/CD
id/JJ
of/IN
2Xhybridization/JJ
buffer/NN
(/(
Agilent/JJ
Technologies/NNS
)/)
./.
====================
The/DT
mixture/NN
was/VBD
centrifuged/JJ
at/IN
12,000/CD
rpm/NN
for/IN
3/CD
min/NN
after/IN
it/PRP
was/VBD
boiled/VBN
for/IN
2/CD
min/NN
./.
====================
About/RB
24/CD
id/JJ
of/IN
the/DT
mixture/NN
was/VBD
hybridized/VBN
on/IN
the/DT
array/NN
at/IN
65/CD
°C/NN
for/IN
16/CD
h./RB
After/IN
hybridization/NN
,/,
the/DT
array/NN
was/VBD
washed/VBN
with/IN
solution/NN
I/NN
(/(
0.5xSSC/JJ
,/,
0.01/CD
%/NN
SDS/NN
,/,
and/CC
1/CD
mM/NN
DTT/NN
in/IN
nuclease-free/JJ
water/RB
)/)
,/,
solution/NN
II/CD
(/(
0.25xSSC/CD
,/,
0.01/CD
%/NN
SDS/NN
,/,
and/CC
1/CD
mM/NN
DTT/NN
in/IN
nuclease-free/JJ
water/RB
)/)
,/,
and/CC
solution/NN
III/CD
(/(
0.06xSSC/CD
and/CC
1/CD
mM/NN
DTT/NN
in/IN
nuclease-free/JJ
water/RB
)/)
respectively/RB
./.
====================
Cy3/NN
and/CC
Cy5/NN
fluorescent/JJ
intensities/NNS
were/VBD
determined/VBN
using/VBG
the/DT
GenePix/NN
scanner/NN
(/(
Axon/JJ
Instruments/NNS
)/)
,/,
and/CC
images/VBZ
were/VBD
analyzed/VBN
using/VBG
the/DT
built-in/JJ
program/NN
to/TO
calculate/JJ
relative/JJ
ratios/NNS
and/CC
to/TO
determine/VB
confidence/NN
intervals/NNS
./.
====================
Fluorescence/NN
intensity/NN
was/VBD
processed/VBN
and/CC
measured/VBD
using/VBG
GenePix/JJ
Pro/NN
software/JJ
(/(
Axon/JJ
Instruments/NNS
)/)
./.
====================
Intensity/NN
data/NNS
were/VBD
imported/VBN
to/TO
an/DT
in-house/JJ
microarray/NN
database/NN
./.
====================
Variance/NN
stabilizing/VBG
normalization/NN
by/IN
Huber/NN
et/FW
al/JJ
./.
====================
was/VBD
applied/VBN
with/IN
the/DT
‘/NN
vsn/NN
’/CD
package/NN
in/IN
Bioconductor/NN
using/VBG
the/DT
R/NN
statistical/JJ
package/NN
./.
====================
After/IN
performing/VBG
intensity-dependent/JJ
global/JJ
LOWESS/NN
regression/NN
,/,
spatial/JJ
and/CC
intensity/NN
dependent/JJ
effects/NNS
were/VBD
managed/VBN
by/IN
pin-group/NN
LOWESS/NN
normalization/NN
following/VBG
by/IN
the/DT
approach/NN
of/IN
Yang/NN
et/FW
al/JJ
./.
====================
A/DT
variation/NN
filter/JJR
was/VBD
used/VBN
to/TO
reduce/VB
the/DT
number/NN
of/IN
genes/NNS
for/IN
the/DT
following/VBG
cluster/NN
analysis/NN
./.
====================
Specifically/RB
,/,
we/PRP
applied/VBD
the/DT
non-parametric/JJ
Kruskall-Wallis/JJ
one-way/NN
analysis/NN
of/IN
variance/NN
to/TO
eliminate/VB
the/DT
genes/NNS
that/WDT
did/VBD
not/RB
change/VB
significantly/RB
across/IN
samples/NNS
./.
====================
Host/NN
responses/NNS
to/TO
mycoplasma/NN
infection/NN
were/VBD
tested/VBN
in/IN
====================
two/CD
different/JJ
human/JJ
cell/NN
lines/NNS
,/,
HeLa/NN
and/CC
293/CD
,/,
which/WDT
is/VBZ
usually/RB
used/VBN
by/IN
molecular/JJ
biology/NN
experiments/NNS
./.
====================
Subconfluent/JJ
cells/NNS
at/IN
2-5x10/CD
6/CD
cells/NNS
per/IN
100/CD
mm/NN
dish/VBP
were/VBD
incubated/VBN
with/IN
mycoplasma/NN
pellet/NN
at/IN
the/DT
concentration/NN
of/IN
10/CD
8/CD
per/IN
10/CD
ml/NN
media/NNS
./.
====================
Gross/NN
morphology/NN
of/IN
each/DT
cells/NNS
was/VBD
not/RB
significantly/RB
changed/VBD
upon/IN
microbial/JJ
infections/NNS
./.
====================
To/TO
stabilize/VB
the/DT
host­/NN
pathogen/NN
interaction/NN
,/,
we/PRP
incubated/VBD
cells/NNS
with/IN
Mycoplasma/NN
for/IN
48/CD
h./FW
The/DT
transcripts/NNS
of/IN
infected/JJ
cells/NNS
were/VBD
compared/VBN
with/IN
uninfected/JJ
control/NN
cells/NNS
./.
====================
Overall/RB
expression/NN
similarities/NNS
for/IN
each/DT
samples/NNS
of/IN
microarray/NN
data/NNS
is/VBZ
provided/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
These/DT
measures/NNS
in/IN
the/DT
table/JJ
are/VBP
calculated/VBN
as/IN
a/DT
pattern-similarity/NN
of/IN
two/CD
samples/NNS
./.
====================
The/DT
absolute/JJ
value/NN
of/IN
Pearson/NN
correlation/NN
coefficient/JJ
is/VBZ
used/VBN
for/IN
the/DT
pattern-similarity/NN
./.
====================
According/VBG
to/TO
====================
the/DT
figure/NN
,/,
we/PRP
observe/VBP
that/DT
characteristics/NNS
of/IN
host/NN
response/NN
to/TO
mycoplasma/NN
have/VBP
remarkable/JJ
difference/NN
in/IN
two/CD
different/JJ
cell/NN
lines/NNS
./.
====================
Selection/NN
of/IN
biomarkers/NNS
for/IN
Mycoplasma/NN
infection/NN
====================
From/IN
the/DT
quadruplicated/JJ
profile/NN
of/IN
10K/NN
oligonucleotide/NN
microarray/NN
in/IN
each/DT
cells/NNS
,/,
we/PRP
selected/VBD
genes/NNS
for/IN
the/DT
host/NN
====================
responses/NNS
to/TO
mycoplasma/NN
infection/NN
under/IN
the/DT
following/VBG
standards/NNS
(/(
Table/JJ
1/CD
)/)
:/:
====================
i/LS
)/)
Standard/JJ
deviation/NN
in/IN
both/DT
of/IN
infected/JJ
and/CC
control/JJ
groups/NNS
should/MD
be/VB
less/RBR
than/IN
two/CD
fold/JJ
in/IN
both/DT
cell/NN
lines/NNS
,/,
ii/LS
)/)
Average/JJ
fold/JJ
activation/NN
of/IN
infected/JJ
groups/NNS
should/MD
exceed/RB
two/CD
fold/JJ
,/,
iii/LS
)/)
Average/JJ
fold/JJ
activation/NN
of/IN
uninfected/JJ
control/NN
group/NN
should/MD
be/VB
less/RBR
than/IN
two/CD
fold/JJ
,/,
iv/LS
)/)
Activation/NN
of/IN
gene/NN
====================
expression/NN
should/MD
be/VB
found/VBN
in/IN
both/CC
of/IN
HeLa/NN
and/CC
293/CD
cells/NNS
./.
====================
According/VBG
to/TO
the/DT
GO/NN
(/(
http/NN
:/:
//www.geneontology.org//JJ
)/)
,/,
we/PRP
could/MD
classify/VB
these/DT
30/CD
genes/NNS
in/IN
their/PRP$
biological/JJ
functions/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
view/NN
of/IN
biological/JJ
effect/NN
of/IN
Mycoplasma/NN
infection/NN
,/,
we/PRP
found/VBD
that/IN
two/CD
categories/NNS
of/IN
genes/NNS
like/IN
cell/NN
cycle/proliferation/NN
and/CC
immune/JJ
response/NN
were/VBD
changed/VBN
upon/IN
the/DT
infection/NN
./.
====================
Especially/RB
Mycoplasma/NN
leads/VBZ
to/TO
the/DT
growth/NN
retardation/NN
or/CC
arrest/NN
in/IN
vitro/FW
,/,
which/WDT
might/MD
be/VB
explained/VBN
by/IN
the/DT
transcriptional/JJ
activation/NN
of/IN
genes/NNS
like/IN
PR48/NN
,/,
MADH4/NN
and/CC
MKPX/NN
./.
====================
Although/IN
two/CD
cell/NN
lines/NNS
were/VBD
not/RB
from/IN
immunological/JJ
tissues/NNS
,/,
we/PRP
detected/VBD
the/DT
increase/NN
of/IN
transcripts/NNS
like/IN
IL1HY1/NN
,/,
KLRF1/NN
,/,
TNFSF14/NN
and/CC
GBP1/NN
./.
====================
Prediction/NN
model/NN
for/IN
Mycoplasma/NN
contamination/NN
====================
The/DT
30/CD
genes/NNS
selected/VBN
significantly/RB
,/,
listed/VBN
in/IN
Table/JJ
1/CD
,/,
are/VBP
believed/VBN
that/IN
they/PRP
are/VBP
strongly/RB
involved/VBN
the/DT
process/NN
of/IN
mycoplasma/NN
infection/NN
in/IN
human/JJ
cells/NNS
./.
====================
From/IN
this/DT
fact/NN
,/,
we/PRP
define/VBP
the/DT
contamination/NN
index/NN
for/IN
a/DT
given/VBN
sample/NN
of/IN
====================
microarray/NN
,/,
as/IN
follows/VBZ
:/:
====================
where/WRB
{/CD
g1/NN
,/,
.../:
,/,
g30/CD
}/CD
is/VBZ
the/DT
set/NN
of/IN
gene/NN
in/IN
Table/JJ
1/CD
,/,
M/NN
(/(
g/NN
,/,
s/NNS
)/)
====================
is/VBZ
the/DT
log-ratio/NN
of/IN
expression/NN
of/IN
g/NN
under/IN
the/DT
sample/NN
s/NNS
,/,
and/CC
it/PRP
is/VBZ
the/DT
====================
function/NN
t/NN
hat/VBP
indicate/VBP
the/DT
====================
probability/NN
of/IN
a/DT
gene/NN
with/IN
expression/NN
value/NN
x/NN
became/VBD
a/DT
differentially/RB
expressed/VBN
gene/NN
./.
====================
Since/IN
these/DT
genes/NNS
are/VBP
differentially/RB
expressed/VBN
in/IN
both/CC
====================
cells/NNS
,/,
we/PRP
may/MD
consider/VB
that/DT
the/DT
contamination/NN
index/NN
Cl/NN
(/(
s/NNS
)/)
reflects/VBZ
that/DT
whether/IN
the/DT
unknown/JJ
sample/NN
s/NNS
is/VBZ
infected/VBN
by/IN
Mycoplasma/NN
or/CC
not/RB
./.
====================
To/TO
give/VB
a/DT
specific/JJ
criterion/NN
for/IN
mycoplasma/NN
contamination/NN
,/,
we/PRP
calculated/VBD
the/DT
contamination/NN
indices/VBZ
with/IN
respect/NN
to/TO
the/DT
randomly/RB
selected/VBN
genes/NNS
./.
====================
Mean/JJ
values/NNS
and/CC
standard/JJ
deviations/NNS
of/IN
the/DT
indices/NNS
for/IN
each/DT
samples/NNS
are/VBP
extracted/VBN
by/IN
iterating/VBG
these/DT
process/NN
1,000/CD
times/NNS
./.
====================
Parameters/NNS
in/IN
random/JJ
model/NN
are/VBP
listed/VBN
in/IN
Table/JJ
2/CD
./.
====================
We/PRP
set/VBP
a/DT
criterion/JJ
to/TO
predict/VB
contamination/NN
by/IN
Mycoplasma/NN
====================
for/IN
a/DT
given/VBN
sample/NN
s/NNS
as/IN
follows/VBZ
:/:
====================
Cl/NN
(/(
s/NNS
)/)
>/JJR
m/NN
+/JJ
3V/NN
,/,
====================
where/WRB
m/NN
and/CC
a/DT
are/VBP
mean/JJ
and/CC
standard/JJ
deviation/NN
in/IN
random/JJ
model/NN
,/,
respectively/RB
./.
====================
The/DT
threshold/JJ
“/CD
m+3V/NN
”/CD
is/VBZ
taken/VBN
to/TO
satisfy/JJ
that/DT
the/DT
false/NN
positive/JJ
rate/NN
is/VBZ
less/RBR
than/IN
0.01/CD
./.
====================
That/DT
is/VBZ
,/,
the/DT
probability/NN
of/IN
Cl/NN
(/(
s/NNS
)/)
>/JJR
m+3V/NN
when/WRB
s/NNS
is/VBZ
not/RB
contaminated/VBN
by/IN
Mycoplasma/NN
is/VBZ
less/RBR
than/IN
0.01/CD
./.
====================
According/VBG
to/TO
the/DT
Table/JJ
2/CD
,/,
only/RB
the/DT
case/NN
of/IN
sample/JJ
“/CD
293/CD
cell-replication/NN
2/CD
”/CD
fails/VBZ
to/TO
predict/VB
the/DT
mycoplasma/NN
contamination/NN
out/RP
of/IN
8/CD
total/JJ
samples/NNS
./.
====================
In/IN
the/DT
sample/JJ
“/RB
293/CD
cell-replication/JJ
2/CD
”/NNP
,/,
we/PRP
observe/VBP
that/DT
the/DT
contamination/NN
index/NN
(/(
0.16773/CD
)/)
is/VBZ
much/RB
larger/RBR
than/IN
the/DT
mean/JJ
contamination/NN
index/NN
(/(
0.0857/CD
)/)
for/IN
randomly/RB
selected/VBN
genes/NNS
,/,
but/CC
the/DT
standard/JJ
deviation/NN
(/(
0.0431/CD
)/)
is/VBZ
relatively/RB
large/JJ
to/TO
the/DT
contamination/NN
index/NN
,/,
so/RB
the/DT
log-expression/NN
profile/NN
in/IN
the/DT
sample/JJ
is/VBZ
far/RB
from/IN
the/DT
normal/JJ
distribution/NN
,/,
which/WDT
is/VBZ
a/DT
basic/JJ
assumption/NN
of/IN
our/PRP$
predicting/VBG
model/NN
./.
====================
Efforts/NNS
in/IN
functional/JJ
genomics/NNS
related/JJ
to/TO
cancer/NN
research/NN
have/VBP
yielded/VBN
major/JJ
successes/NNS
in/IN
the/DT
pursuit/NN
of/IN
gene/NN
expression/NN
signatures/NNS
./.
====================
Approaches/NNS
for/IN
gene/NN
expression/NN
analysis/NN
,/,
such/JJ
as/IN
time-series/NNS
analysis/NN
,/,
pattern/NN
discovery/NN
,/,
clustering/NN
,/,
and/CC
class/NN
prediction/NN
,/,
have/VBP
been/VBN
recently/RB
reviewed/VBD
(/(
Solnim/NN
,/,
2002/CD
)/)
./.
====================
Expression-based/VBN
criteria/NNS
or/CC
class/NN
predictors/NNS
have/VBP
been/VBN
defined/VBN
based/VBN
on/IN
neighborhood/JJ
analysis/NN
(/(
Golub/NNP
,/,
1999/CD
)/)
,/,
a/DT
supervised/VBN
method/NN
based/VBN
on/IN
a/DT
subset/NN
of/IN
genes/NNS
whose/WP$
expression/NN
strongly/RB
correlates/VBZ
with/IN
specific/JJ
classes/NNS
,/,
as/IN
well/RB
as/IN
Bayesian/JJ
regression/NN
models/NNS
(/(
West/NNP
,/,
2001/CD
)/)
and/CC
artificial/JJ
neural/JJ
networks/NNS
(/(
Khan/NNP
,/,
2001/CD
)/)
./.
====================
These/DT
predictors/NNS
were/VBD
successfully/RB
used/VBN
to/TO
classify/VB
novel/JJ
samples/NNS
in/IN
a/DT
manner/NN
consistent/JJ
with/IN
clinical/JJ
assessments/NNS
./.
====================
In/IN
fact/NN
,/,
classifications/NNS
based/VBN
on/IN
gene/NN
expression/NN
alone/RB
or/CC
class/NN
discovery/NN
have/VBP
also/RB
been/VBN
====================
demonstrated/VBD
and/CC
suggesting/VBG
that/IN
gene/NN
expression/NN
profiling/VBG
have/VBP
the/DT
capacity/NN
to/TO
identify/VB
subtypes/NNS
that/WDT
have/VBP
not/RB
been/VBN
previously/RB
defined/VBN
(/(
Golub/NN
,/,
1999/CD
)/)
./.
====================
Although/IN
these/DT
results/NNS
are/VBP
promising/VBG
,/,
one/CD
should/MD
note/VB
that/IN
many/JJ
of/IN
the/DT
previously/RB
conducted/VBN
cancer/NN
line/NN
gene/NN
expression/NN
analyses/NNS
are/VBP
one/CD
dimensional/JJ
;/:
in/IN
contrast/NN
,/,
a/DT
host/NN
expression/NN
profile/NN
evoked/VBN
by/IN
pathogen/NN
exposure/NN
would/MD
be/VB
expected/VBN
to/TO
be/VB
temporal/JJ
and/CC
may/MD
also/RB
exhibit/VBP
dose/NN
dependence/NN
./.
====================
Comprehensive/JJ
sets/NNS
of/IN
gene/NN
expression/NN
profiles/NNS
that/WDT
explore/VBP
temporal/JJ
and/CC
dose/NN
ranges/NNS
for/IN
pathogen/NN
exposure/NN
must/MD
be/VB
produced/VBN
to/TO
map/VB
the/DT
continuum/NN
of/IN
gene/NN
expression/NN
changes/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
suggested/VBD
a/DT
list/NN
of/IN
genes/NNS
that/WDT
is/VBZ
believed/VBN
to/TO
strongly/RB
related/JJ
to/TO
the/DT
mycoplasma/NN
contamination/NN
in/IN
two/CD
different/JJ
human/JJ
cell/NN
lines/NNS
,/,
HeLa/NN
and/CC
293/CD
./.
====================
We/PRP
also/RB
suggested/VBD
a/DT
model/NN
to/TO
predict/VB
that/DT
a/DT
given/VBN
sample/NN
is/VBZ
infected/VBN
by/IN
the/DT
mycoplasma/NN
./.
====================
This/DT
naive/JJ
process/NN
has/VBZ
strong/JJ
power/JJR
to/TO
predict/VB
,/,
and/CC
is/VBZ
suitable/JJ
to/TO
the/DT
our/PRP$
data/NNS
which/WDT
has/VBZ
unique/JJ
structure/NN
that/DT
consisted/VBD
of/IN
expression/NN
of/IN
genes/NNS
upon/IN
infection/NN
in/IN
various/JJ
experimental/JJ
conditions/NNS
such/JJ
as/IN
cell-lines/NNS
or/CC
dose/NN
ranges/NNS
./.
====================
To/TO
get/VB
a/DT
more/RBR
strong/JJ
prediction/NN
power/JJR
for/IN
overall-non-contamination/NN
of/IN
a/DT
concerned/JJ
sample/NN
,/,
we/PRP
need/VBD
a/DT
structural/JJ
experimental/JJ
profiling/VBG
data/NNS
for/IN
host/NN
response/NN
of/IN
infection/NN
by/IN
wide/JJ
source/NN
of/IN
pathogens/NNS
./.
====================
